심근경색(MI) 치료제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2031년)

Myocardial Infarction (MI) Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

US $ 4,995 ￦ 6,919,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,105,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,768,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 최근 심근경색(MI) 치료제 세계 시장에 대한 종합적인 보고서를 발표했습니다. 이 보고서는 시장 동인, 동향, 기회, 촉진요인, 도전 과제 등 주요 시장 역학을 철저히 평가하고 시장 구조에 대한 심층적인 통찰력을 제공합니다. 이 보고서는 2024년부터 2031년까지 세계 심근경색 치료제 시장 예측 성장 궤적을 개괄하는 독점 데이터와 통계를 제공합니다.

주요 인사이트

• MI 치료제 시장 규모(2024년) : 226억 7,000만 달러
• 예상 시장 규모(2031년) : 303억 달러
• 세계 시장 성장률(2024-2031년 CAGR) : 4.2%

심근경색 치료제 시장-조사 범위

심근경색은 일반적으로 심장마비로 알려져 있으며, 전 세계적으로 이환율과 사망률의 주요 원인으로 꼽힙니다. 심근경색 치료제는 급성 심근경색을 관리하고 향후 심혈관 질환을 예방하기 위한 약수처리, 수술적 중재, 생활습관 개선 등 다양한 치료법을 포함합니다. 이 시장은 병원, 외래진료소, 재활센터 등에 서비스를 제공하며 항혈소판제, 베타차단제, ACE 억제제, 스타틴, PCSK9 억제제와 같은 새로운 치료제를 포함한 다양한 치료제를 제공합니다. 시장 성장의 원동력은 심혈관 질환의 유병률 증가, 치료 옵션의 발전, 의료비 지출 증가 등입니다.

시장 성장 촉진요인:

세계 심근경색증 치료제 시장은 생활습관의 변화, 인구 고령화, 고혈압, 당뇨병, 비만과 같은 위험요인의 유병률 증가로 인한 심혈관 질환 발병률 증가 등 몇 가지 중요한 요인에 의해 주도되고 있습니다. 또한, 새로운 제제 및 치료 전략의 개발로 치료 효과와 환자 예후가 개선되고 있습니다. 조기 개입과 예방 조치의 중요성에 대한 인식이 높아진 것도 시장 확대에 기여하고 있습니다. 또한, 의료 인프라의 확대와 심장 치료 서비스에 대한 접근성 향상도 시장 성장에 중요한 역할을 하고 있습니다.

시장 성장 억제요인 :

유망한 성장 전망에도 불구하고, 심근경색증 치료제 시장은 높은 치료 비용, 엄격한 규제 당국의 승인, 지속적인 환자 모니터링의 필요성과 관련된 문제에 직면해 있습니다. 혁신적인 치료제와 첨단 수술에 따른 높은 비용은 특히 신흥 경제국에서 특정 환자 집단의 접근성을 제한할 수 있습니다. 또한, 규제 장벽과 긴 신약 승인 절차는 새로운 치료제 시장 진입을 저해할 수 있습니다. 재발 방지를 위해서는 생활습관 개선이 중요하기 때문에 환자가 처방된 치료 요법을 잘 따르는 것도 중요한 과제입니다.

시장 기회 :

심근경색증 치료제 시장은 기술 혁신, 인구 변화, 진화하는 의료 서비스 제공 모델로 인해 큰 성장 기회를 맞이하고 있습니다. 원격 의료 플랫폼 및 원격 모니터링 장비와 같은 디지털 건강 기술의 통합은 환자의 MI 관리 서비스에 대한 접근성을 높이고 치료 순응도를 향상시킬 수 있습니다. 또한, 개인 맞춤형 의료와 맞춤형 치료 접근법에 대한 관심이 높아지면서 기술 혁신을 촉진하고 치료 옵션을 확대할 수 있습니다. 새로운 기회를 활용하고 시장 발전을 촉진하기 위해서는 제약사, 의료 서비스 제공업체 및 연구 기관 간의 전략적 제휴가 필수적입니다.

본 보고서에서 다룬 주요 질문들

• MI 치료제 시장의 세계 성장을 가속하는 주요 요인은?
• 다양한 의료 환경에서 어떤 치료 유형과 치료 방식이 지지를 받고 있는가?
• 기술의 발전은 MI 치료제 시장 경쟁 구도를 어떻게 변화시키고 있는가?
• MI 치료제 시장에 기여하는 주요 기업들은 어디에 있으며, 시장 관련성을 유지하기 위해 어떤 전략을 채택하고 있는가?
• 세계 MI 치료제 시장의 새로운 트렌드와 미래 전망은?

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위와 정의
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
  • 주요 동향
• 거시경제 요인
  • 세계의 부문별 전망
  • 세계의 GDP 성장 전망
  • 세계의 의료비 지출 전망
• COVID-19의 영향 분석
• 예측 요인 - 관련성과 영향

제3장 부가가치 통찰

• 제품 채택 분석
• 기술 평가
• 규제 상황
• 밸류체인 분석
  • 유통 채널/마켓플레이스 리스트
    • 소매
    • 청각학
    • E-Commerce
  • 최종사용자(업계) 리스트
• 주요 거래와 합병
• PESTLE 분석
• Porter의 Five Forces 분석

제4장 세계의 심근경색(MI) 치료제 시장 전망 : 실적(2019년-2023년) 및 예측(2024년-2031년)

• 주요 하이라이트
  • 시장 규모와 전년대비 성장률
  • 절대적인$기회
• 시장 규모 분석과 예측
  • 과거 시장 규모 분석, 2019년-2023년
  • 현재 시장 규모 분석과 예측, 2024년-2031년
• 세계의 심근경색(MI) 치료제 시장 전망 : 약제 유형별
  • 서론/주요 조사 결과
  • 과거 시장 규모 분석 : 약제 유형별, 2019년-2023년
  • 현재 시장 규모 분석과 예측 : 약제 유형별, 2024년-2031년
    • 항혈소판제
    • 당단백질 IIb/IIIa 억제제
    • 항혈전제
    • 베타 차단제
• 시장의 매력 분석 : 약제 유형별
• 세계의 심근경색(MI) 치료제 시장 전망 : 투여 경로별
  • 서론/주요 조사 결과
  • 과거 시장 규모 분석 : 투여 경로별, 2019년-2023년
  • 현재 시장 규모 분석과 예측 : 투여 경로별, 2024년-2031년
    • 경구
    • 주사 가능
• 시장의 매력 분석 : 투여 경로별
• 세계의 심근경색(MI) 치료제 시장 전망 : 유통 채널별
  • 서론/주요 조사 결과
  • 과거 시장 규모 분석 : 유통 채널별, 2019년-2023년
  • 현재 시장 규모 분석과 예측 : 유통 채널별, 2024년-2031년
    • 병원
    • 클리닉
    • 소매 약국
    • 온라인 약국
• 시장의 매력 분석 : 유통 채널

제5장 세계의 심근경색(MI) 치료제 시장 전망 : 지역별

• 주요 하이라이트
• 과거 시장 규모 분석 : 지역별, 2019년-2023년
• 현재 시장 규모 분석과 예측 : 지역별, 2024년-2031년
  • 북미
  • 유럽
  • 동아시아
  • 남아시아 및 오세아니아
  • 라틴아메리카
  • 중동 및 아프리카
• 시장의 매력 분석 : 지역별

제6장 북미 심근경색(MI) 치료제 시장 전망 : 실적(2019년-2023년) 및 예측(2024년-2031년)

제7장 유럽 심근경색(MI) 치료제 시장 전망 : 실적(2019년-2023년) 및 예측(2024년-2031년)

제8장 동아시아 심근경색(MI) 치료제 시장 전망 : 실적(2019년-2023년) 및 예측(2024년-2031년)

제9장 남아시아 및 오세아니아 심근경색(MI) 치료제 시장 전망 : 실적(2019년-2023년) 및 예측(2024년-2031년)

제10장 북미 심근경색(MI) 치료제 시장 전망 : 실적(2019년-2023년) 및 예측(2024년-2031년)

제11장 중동 및 아프리카 심근경색(MI) 치료제 시장 전망 : 실적(2019년-2023년) 및 예측(2024년-2031년)

제12장 경쟁 구도

• 시장 점유율 분석, 2024년
• 시장 구조
  • 시장별 경쟁 강도 매핑
  • 경쟁 대시보드
• 기업 개요(상세 - 개요, 재무, 전략, 최근 동향)
  • Bayer HealthCare LLC
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • Janssen Biotech, Inc.
  • Merck &Co. Inc.
  • Novartis International AG
  • Sanofi
  • AstraZeneca
  • Pfizer
  • Amgen, Inc
  • GlaxoSmithKline PLC
  • Regeneron Pharmaceuticals Inc.
  • Bristol-Myers Squibb Company
  • Alnylam Pharmaceuticals Inc.

제13장 부록

• 조사 방법
• 조사 전제
• 두자어 및 약어

LSH

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the worldwide market for myocardial infarction (MI) therapeutics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global MI therapeutics market from 2024 to 2031.

Key Insights:

• MI Therapeutics Market Size (2024E): US$22.67 Bn
• Projected Market Value (2031F): US$30.3 Bn
• Global Market Growth Rate (CAGR 2024 to 2031):4.2%

MI Therapeutics Market - Report Scope:

Myocardial infarction, commonly known as a heart attack, is a leading cause of morbidity and mortality worldwide. MI therapeutics include a range of treatment modalities such as medications, surgical interventions, and lifestyle modifications aimed at managing acute myocardial infarction and preventing future cardiovascular events. The market serves hospitals, outpatient clinics, and rehabilitation centers, providing a variety of therapeutics, including antiplatelet agents, beta-blockers, ACE inhibitors, statins, and novel therapies like PCSK9 inhibitors. Market growth is driven by the increasing prevalence of cardiovascular diseases, advancements in therapeutic options, and rising healthcare expenditures.

Market Growth Drivers:

The global MI therapeutics market is propelled by several key factors, including the rising incidence of cardiovascular diseases due to lifestyle changes, aging populations, and the increasing prevalence of risk factors such as hypertension, diabetes, and obesity. Furthermore, the development of novel drug formulations and treatment strategies enhances therapeutic efficacy and patient outcomes. Growing awareness about the importance of early intervention and preventive measures also contributes to market expansion. Additionally, the expansion of healthcare infrastructure and improved access to cardiac care services play a crucial role in supporting market growth.

Market Restraints:

Despite promising growth prospects, the MI therapeutics market faces challenges related to high treatment costs, stringent regulatory approvals, and the need for continuous patient monitoring. The high costs associated with innovative therapeutics and advanced surgical procedures may limit access for certain patient populations, particularly in developing economies. Moreover, regulatory hurdles and the lengthy approval processes for new drugs can impede market entry for novel therapeutics. Ensuring patient adherence to prescribed treatment regimens also remains a challenge, as lifestyle modifications are crucial for preventing recurrent events.

Market Opportunities:

The MI therapeutics market presents significant growth opportunities driven by technological innovations, demographic trends, and evolving healthcare delivery models. The integration of digital health technologies, such as telehealth platforms and remote monitoring devices, enhances patient access to MI management services and improves adherence to treatment. Additionally, the growing focus on personalized medicine and tailored therapeutic approaches can stimulate innovation and expand treatment options. Strategic partnerships between pharmaceutical companies, healthcare providers, and research institutions are essential to capitalize on emerging opportunities and drive market advancements.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the MI therapeutics market globally?
• Which therapeutic classes and treatment modalities are gaining traction across different healthcare settings?
• How are technological advancements reshaping the competitive landscape of the MI therapeutics market?
• Who are the key players contributing to the MI therapeutics market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global MI therapeutics market?

Competitive Intelligence and Business Strategy:

Leading players in the global MI therapeutics market, including Pfizer Inc., Novartis AG, Johnson & Johnson, and AstraZeneca, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced therapeutics, including novel antiplatelet agents, beta-blockers, and emerging therapies for heart failure management. Collaborations with healthcare providers, academic institutions, and regulatory agencies facilitate market access and promote technology adoption. Moreover, an emphasis on clinical research, evidence-based practice, and patient education enhances market growth and improves patient outcomes in the rapidly evolving MI therapeutics landscape.

Key Companies Profiled:

• Pfizer Inc.
• Novartis AG
• Johnson & Johnson
• AstraZeneca
• Bristol-Myers Squibb Company
• Sanofi S.A.
• Bayer AG
• Boehringer Ingelheim GmbH
• Amgen Inc.
• Gilead Sciences, Inc.

Myocardial Infarction (MI) Therapeutics Market Segmentation

By Drug Type

• Antiplatelet Agents
• Glycoprotein IIb/IIIa Inhibitors
• Antithrombotic Agents
• Beta-adrenergic Blockers

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Hospitals
• Clinics
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• East Asia
• South Asia & Pacific
• Middle East and Africa
• Latin America

Table of Contents

1. Executive Summary

• 1.1. Global Myocardial Infarction (MI) Therapeutics Market Snapshot, 2024-2031
• 1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Product Adoption Analysis
• 3.2. Technology Assessment
• 3.3. Regulatory Landscape
• 3.4. Value Chain Analysis
  • 3.4.1. List of Distribution Channel/Marketplaces
    • 3.4.1.1. Retail
    • 3.4.1.2. Audiology
    • 3.4.1.3. E-Commerce
  • 3.4.2. List of End User (Industry)
• 3.5. Key Deals and Mergers
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis

4. Global Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2023
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2024-2031
• 4.3. Global Myocardial Infarction (MI) Therapeutics Market Outlook: Drug Type
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Drug Type, 2019-2023
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
    • 4.3.3.1. Antiplatelet Agents
    • 4.3.3.2. Glycoprotein IIb/IIIa Inhibitors
    • 4.3.3.3. Antithrombotic Agents
    • 4.3.3.4. Beta-adrenergic Blockers
• 4.4. Market Attractiveness Analysis: Drug Type
• 4.5. Global Myocardial Infarction (MI) Therapeutics Market Outlook: Route of Administration
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn) Analysis, By Route of Administration, 2019-2023
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
    • 4.5.3.1. Oral
    • 4.5.3.2. Injectable
• 4.6. Market Attractiveness Analysis: Route of Administration
• 4.7. Global Myocardial Infarction (MI) Therapeutics Market Outlook: Distribution Channel
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2023
  • 4.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
    • 4.7.3.1. Hospitals
    • 4.7.3.2. Clinics
    • 4.7.3.3. Retail Pharmacies
    • 4.7.3.4. Online Pharmacies
• 4.8. Market Attractiveness Analysis: Distribution Channel

5. Global Myocardial Infarction (MI) Therapeutics Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2024-2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 6.1. Key Highlights
• 6.2. Pricing Analysis
• 6.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 6.3.1. By Country
  • 6.3.2. By Drug Type
  • 6.3.3. By Route of Administration
  • 6.3.4. By Distribution Channel
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 6.4.1. U.S.
  • 6.4.2. Canada
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
  • 6.5.1. Antiplatelet Agents
  • 6.5.2. Glycoprotein IIb/IIIa Inhibitors
  • 6.5.3. Antithrombotic Agents
  • 6.5.4. Beta-adrenergic Blockers
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 6.6.1. Oral
  • 6.6.2. Injectable
• 6.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 6.7.1. Hospitals
  • 6.7.2. Clinics
  • 6.7.3. Retail Pharmacies
  • 6.7.4. Online Pharmacies
• 6.8. Market Attractiveness Analysis

7. Europe Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 7.1. Key Highlights
• 7.2. Pricing Analysis
• 7.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 7.3.1. By Country
  • 7.3.2. By Drug Type
  • 7.3.3. By Route of Administration
  • 7.3.4. By Distribution Channel
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. U.K.
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Russia
  • 7.4.7. Turkiye
  • 7.4.8. Rest of Europe
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
  • 7.5.1. Antiplatelet Agents
  • 7.5.2. Glycoprotein IIb/IIIa Inhibitors
  • 7.5.3. Antithrombotic Agents
  • 7.5.4. Beta-adrenergic Blockers
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 7.6.1. Oral
  • 7.6.2. Injectable
• 7.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 7.7.1. Hospitals
  • 7.7.2. Clinics
  • 7.7.3. Retail Pharmacies
  • 7.7.4. Online Pharmacies
• 7.8. Market Attractiveness Analysis

8. East Asia Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 8.1. Key Highlights
• 8.2. Pricing Analysis
• 8.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 8.3.1. By Country
  • 8.3.2. By Drug Type
  • 8.3.3. By Route of Administration
  • 8.3.4. By Distribution Channel
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. South Korea
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
  • 8.5.1. Antiplatelet Agents
  • 8.5.2. Glycoprotein IIb/IIIa Inhibitors
  • 8.5.3. Antithrombotic Agents
  • 8.5.4. Beta-adrenergic Blockers
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 8.6.1. Oral
  • 8.6.2. Injectable
• 8.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 8.7.1. Hospitals
  • 8.7.2. Clinics
  • 8.7.3. Retail Pharmacies
  • 8.7.4. Online Pharmacies
• 8.8. Market Attractiveness Analysis

9. South Asia and Oceania Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 9.1. Key Highlights
• 9.2. Pricing Analysis
• 9.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 9.3.1. By Country
  • 9.3.2. By Drug Type
  • 9.3.3. By Route of Administration
  • 9.3.4. By Distribution Channel
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 9.4.1. India
  • 9.4.2. Southeast Asia
  • 9.4.3. ANZ
  • 9.4.4. Rest of South Asia & Oceania
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
  • 9.5.1. Antiplatelet Agents
  • 9.5.2. Glycoprotein IIb/IIIa Inhibitors
  • 9.5.3. Antithrombotic Agents
  • 9.5.4. Beta-adrenergic Blockers
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 9.6.1. Oral
  • 9.6.2. Injectable
• 9.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 9.7.1. Hospitals
  • 9.7.2. Clinics
  • 9.7.3. Retail Pharmacies
  • 9.7.4. Online Pharmacies
• 9.8. Market Attractiveness Analysis

10. North America Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 10.1. Key Highlights
• 10.2. Pricing Analysis
• 10.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 10.3.1. By Country
  • 10.3.2. By Drug Type
  • 10.3.3. By Route of Administration
  • 10.3.4. By Distribution Channel
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 10.4.1. Brazil
  • 10.4.2. Mexico
  • 10.4.3. Rest of Latin America
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
  • 10.5.1. Antiplatelet Agents
  • 10.5.2. Glycoprotein IIb/IIIa Inhibitors
  • 10.5.3. Antithrombotic Agents
  • 10.5.4. Beta-adrenergic Blockers
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 10.6.1. Oral
  • 10.6.2. Injectable
• 10.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 10.7.1. Hospitals
  • 10.7.2. Clinics
  • 10.7.3. Retail Pharmacies
  • 10.7.4. Online Pharmacies
• 10.8. Market Attractiveness Analysis

11. Middle East & Africa Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 11.1. Key Highlights
• 11.2. Pricing Analysis
• 11.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 11.3.1. By Country
  • 11.3.2. By Drug Type
  • 11.3.3. By Route of Administration
  • 11.3.4. By Distribution Channel
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 11.4.1. GCC Countries
  • 11.4.2. Egypt
  • 11.4.3. South Africa
  • 11.4.4. Northern Africa
  • 11.4.5. Rest of Middle East & Africa
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
  • 11.5.1. Antiplatelet Agents
  • 11.5.2. Glycoprotein IIb/IIIa Inhibitors
  • 11.5.3. Antithrombotic Agents
  • 11.5.4. Beta-adrenergic Blockers
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 11.6.1. Oral
  • 11.6.2. Injectable
• 11.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 11.7.1. Hospitals
  • 11.7.2. Clinics
  • 11.7.3. Retail Pharmacies
  • 11.7.4. Online Pharmacies
• 11.8. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Bayer HealthCare LLC
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Boehringer Ingelheim International GmbH
    • 12.3.2.1. Overview
    • 12.3.2.2. Segments and Products
    • 12.3.2.3. Key Financials
    • 12.3.2.4. Market Developments
    • 12.3.2.5. Market Strategy
  • 12.3.3. Eli Lilly and Company
    • 12.3.3.1. Overview
    • 12.3.3.2. Segments and Products
    • 12.3.3.3. Key Financials
    • 12.3.3.4. Market Developments
    • 12.3.3.5. Market Strategy
  • 12.3.4. Janssen Biotech, Inc.
    • 12.3.4.1. Overview
    • 12.3.4.2. Segments and Products
    • 12.3.4.3. Key Financials
    • 12.3.4.4. Market Developments
    • 12.3.4.5. Market Strategy
  • 12.3.5. Merck & Co. Inc.
    • 12.3.5.1. Overview
    • 12.3.5.2. Segments and Products
    • 12.3.5.3. Key Financials
    • 12.3.5.4. Market Developments
    • 12.3.5.5. Market Strategy
  • 12.3.6. Novartis International AG
    • 12.3.6.1. Overview
    • 12.3.6.2. Segments and Products
    • 12.3.6.3. Key Financials
    • 12.3.6.4. Market Developments
    • 12.3.6.5. Market Strategy
  • 12.3.7. Sanofi
    • 12.3.7.1. Overview
    • 12.3.7.2. Segments and Products
    • 12.3.7.3. Key Financials
    • 12.3.7.4. Market Developments
    • 12.3.7.5. Market Strategy
  • 12.3.8. AstraZeneca
    • 12.3.8.1. Overview
    • 12.3.8.2. Segments and Products
    • 12.3.8.3. Key Financials
    • 12.3.8.4. Market Developments
    • 12.3.8.5. Market Strategy
  • 12.3.9. Pfizer
    • 12.3.9.1. Overview
    • 12.3.9.2. Segments and Products
    • 12.3.9.3. Key Financials
    • 12.3.9.4. Market Developments
    • 12.3.9.5. Market Strategy
  • 12.3.10. Amgen, Inc
    • 12.3.10.1. Overview
    • 12.3.10.2. Segments and Products
    • 12.3.10.3. Key Financials
    • 12.3.10.4. Market Developments
    • 12.3.10.5. Market Strategy
  • 12.3.11. GlaxoSmithKline PLC
    • 12.3.11.1. Overview
    • 12.3.11.2. Segments and Products
    • 12.3.11.3. Key Financials
    • 12.3.11.4. Market Developments
    • 12.3.11.5. Market Strategy
  • 12.3.12. Regeneron Pharmaceuticals Inc.
    • 12.3.12.1. Overview
    • 12.3.12.2. Segments and Products
    • 12.3.12.3. Key Financials
    • 12.3.12.4. Market Developments
    • 12.3.12.5. Market Strategy
  • 12.3.13. Bristol-Myers Squibb Company
    • 12.3.13.1. Overview
    • 12.3.13.2. Segments and Products
    • 12.3.13.3. Key Financials
    • 12.3.13.4. Market Developments
    • 12.3.13.5. Market Strategy
  • 12.3.14. Alnylam Pharmaceuticals Inc.
    • 12.3.14.1. Overview
    • 12.3.14.2. Segments and Products
    • 12.3.14.3. Key Financials
    • 12.3.14.4. Market Developments
    • 12.3.14.5. Market Strategy

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료